Martin T, Sharma M, Damon L, Kaplan L, Guglielmo B J, Working M, O'Malley R, Hwang J, Linker C
Division of Hematology/Oncology, University of California-San Francisco, San Francisco, California, USA.
Transpl Infect Dis. 2010 Feb;12(1):45-50. doi: 10.1111/j.1399-3062.2009.00455.x. Epub 2009 Sep 30.
Seventy-two patients undergoing allogeneic transplantation were treated with voriconazole (VOR) as antifungal prophylaxis starting from day -2 of transplantation and continuing until withdrawal of immunosuppression. Patients were assessed for safety and the incidence of definite, probable, or possible fungal infection throughout transplantation was evaluated. VOR was well tolerated. Only 14% of patients required interruption of VOR therapy because of toxicity: liver toxicity (8%), cardiac Q-T interval prolongation (1%), or other side effects (5%). In the early post-transplant period (<120 days), only 2 patients developed invasive fungal infection: 1 mucormycosis infection and 1 disseminated Aspergillus infection. In the late post-transplant period (>120 days), no patients developed probable or definite fungal infection while receiving VOR. No Candida infections were seen in either period. These data suggest that fungal prophylaxis with VOR following allogeneic transplantation is safe and effective.
72例接受同种异体移植的患者从移植前第2天开始接受伏立康唑（VOR）治疗作为抗真菌预防，持续至免疫抑制撤除。评估患者的安全性，并评估整个移植过程中确诊、很可能或可能的真菌感染发生率。VOR耐受性良好。仅14%的患者因毒性需要中断VOR治疗：肝毒性（8%）、心脏Q-T间期延长（1%）或其他副作用（5%）。在移植后早期（<120天），仅2例患者发生侵袭性真菌感染：1例毛霉菌感染和1例播散性曲霉菌感染。在移植后晚期（>120天），接受VOR治疗的患者无很可能或确诊的真菌感染发生。两个时期均未见到念珠菌感染。这些数据表明，同种异体移植后用VOR进行真菌预防是安全有效的。
